期刊
REVISTA ESPANOLA DE CARDIOLOGIA
卷 64, 期 3, 页码 237-239出版社
EDICIONES DOYMA S A
DOI: 10.1016/j.recesp.2011.05.001
关键词
Heart transplantation; Daclizumab; Calcineurin inhibitor
Daclizumab is an interleukin-2 receptor antagonist which is used for induction therapy in heart transplant patients. It has few side effects and is associated with a low infection rate. Postoperative renal failure after heart transplantation is common and potentially fatal. The administration of calcineurin inhibitors in the postoperative period can aggravate the situation. We report the cases of six patients who underwent heart transplantation and developed acute renal failure in the immediate postoperative period. All were administered daclizumab weekly to avoid the introduction of calcineurin inhibitors and to facilitate recovery of renal function. Calcineurin inhibitors were introduced only once renal function had improved. Renal function recovered in all cases and there was a low complication rate. The administration of repeated doses of daclizumab to patients who experience acute postoperative renal failure after heart transplantation may provide an alternative therapeutic approach that enables calcineurin inhibitors to be avoided and, consequently, renal function to recover. Full English text available from: www.revespcardiol.org (C) 2010 Sociedad Espanola de Cardiologia. Published by Elsevier Espana, S.L. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据